Venus Remedies Limited Annual Report FY2026
Venus Remedies Limited Annual Report FY2026
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Venus Remedies Limited (VSR) is a research-oriented pharmaceutical entity specializing in critical care and oncology, notably as a major producer of Meropenem. The secondary analysis of its 10-year journey reveals a business that has emerged from a period of severe financial distress (FY17-FY20) to a state of debt-free stability and renewed growth. While the business possesses substantial intellectual property with 135+ patents and 1,040+ marketing authorizations, its historical inconsistency in profit delivery and high working capital requirements have suppressed long-term value compounding.…
Key Changes in FY2026
The business has undergone a significant transformation from a debt-laden injectable manufacturer to a research-driven, almost debt-free pharmaceutical entity specializing in Antimicrobial Resistance (AMR) drugs. Over the last decade, Venus evolved by focusing on high-value segments like oncology and neurology while building a massive IP portfolio of 135+ patents. The strategic pivot toward export markets and high-margin marketing authorizations (MAs) is evident in the margin expansion from 10% in 2024 to 19% in 2026. This evolution reflects a successful move up the value chain from commodity generics to specialized formulation research. The company's resilience is marked by its ability to maintain its product basket despite severe financial stress during the 2017-2020 period.
Management Commentary
Management has demonstrated resilience and strategic patience during the recovery phase, successfully navigating a debt-trap scenario that would have bankrupted less disciplined firms. Their focus on the 'AMR' (Antimicrobial Resistance) niche and oncology provides a clear thematic direction for the company. Transparency is moderate; while disclosure of marketing authorizations and patent counts is consistent, more clarity is needed on the revenue mix between domestic and international markets. The promoter holding has marginally increased from 37.5% in FY17 to 41.76%, signaling increased management skin in the game. The successful pivot to a debt-free status is a testament to management execution. However, the long period of stagnant sales growth (7% CAGR over 10y) indicates either market…
Financial Highlights
The financial trajectory of Venus Remedies is characterized by a stark 'U-shaped' recovery; revenue remained stagnant between 400Cr and 330Cr during the 2017-2020 period before scaling toward 770Cr in FY26. Operating margins have historically been compressed around 10-11%, but the recent leap to 19% indicates a pivot toward premiumization and cost efficiency. The most notable financial achievement is the elimination of heavy interest costs, which consumed 41Cr in FY15, down to zero in recent years. Net profit has swung from a loss of 31Cr in FY18 to a record 103Cr in FY26. However, return on equity has been historically low, only recently crossing the 15% threshold. Business quality is improving but requires multi-year sustainability to prove the trend is not cyclical.
Major Opportunities
- Successful transition to near debt-free status from high leverage
- Stellar profit growth (174% TTM) indicating business turnaround
- Strong R&D focus with 135+ patents and 1040+ marketing authorizations
Major Risks
- 歷史 recorded a period of 4 consecutive years of net losses (2017-2020)
- Low average Sales growth of ~7% over 5 and 10-year horizons
- High historical dependence on 'Other Income' to drive net profitability in FY21
About This Annual Report
The Venus Remedies Limited FY2026 Annual Report is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.
Why Use AI?
- Summarises hundreds of pages into a focused executive briefing
- Identifies year-on-year key changes automatically
- Extracts management commentary and tone
- Highlights top risks and opportunities
- Compares business evolution vs. earlier years
- Answers your questions in plain English via Ask AI
Frequently Asked Questions
Related Research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.